• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


OSB Lead-Device Failure

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Application Number P090029 / PAS003
Current Plan Approved 03/11/2016
Study Name OSB Lead-Device Failure
General Study Protocol Parameters
Study Design Bench/Lab Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description Objective: to assess long-term modes of device failure. the Design: the study incorporates explant analysis, histopathological analysis using periprosthetic tissues removed during explant surgery, and metal ion testing using blood samples analyzed for trace metal concentrations.

Study Population Description Retrievals from Extended Follow-up of Premarket Cohort, New Enrollment study and other sources (no comparator group)

Sample Size All explanted and retrieved device components which were returned to the company

Data Collection Effectiveness endpoints ? N/A; Safety endpoints: outcomes of explant analysis, histopathological analysis, and metal ion testing with regards to device failure modes

Follow-up Visits and Length of Follow-up N/A

OSB Lead-Device Failure Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 01/22/2015 02/25/2015 Overdue/Received
one year report 07/24/2015 07/17/2015 On Time
18 month report 02/22/2016 01/27/2016 On Time
two year report 07/23/2016 07/20/2016 On Time
three year report 07/23/2017    
four year report 07/23/2018    
five year report 07/23/2019    

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links